Anti-HGFR/c-MET Polyclonal Antibody (HY196014)

Name: Anti-HGFR/c-MET Polyclonal Antibody
Brand: abinScience
SKU: HY196014
Price: 168 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

50ug
100ug

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo

HY196014

Reactividad de especies

Human, Mouse, Rat

Aplicaciones

ELISA, IHC, WB

Especie huésped

Rabbit

Clonalidad

Polyclonal

Isotipo

IgG

Inmunógeno

E. coli - derived recombinant Human MET/c-Met/HGFR (Val1092-Val1379).

Objetivo

Tyrosine-protein kinase Met, Hepatocyte growth factor receptor, Proto-oncogene c-Met, Scatter factor receptor, HGF receptor, SF receptor, HGF/SF receptor, MET

Purificación

Purified by antigen affinity column.

Número de acceso

P08581

Forma

Liquid

Buffer de almacenamiento

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Información de uso del producto

Aplicación	Dilución
ELISA	1:5000-1:20000
IHC	1:50-1:500
WB	1:500-1:2000

Estabilidad y almacenamiento

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Fondo

Hepatocyte growth factor receptor (MET/HGFR) is a ~155 kDa protein. Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. MET is the therapeutic target of amivantamab (Rybrevant).

Nota

For research use only.

Imágenes

Referencias

Datasheet